US FDA Extends Roche’s Risdiplam Decision Date
Move Triggered By Roche’s Submission Of Added Trial Data
The submission of more trial data from Roche has prompted the US FDA to extend by three months its decision on whether to approve risdiplam for spinal muscular atrophy.
